Between 20 and 40% of people with lung cancer develop and die from cancer of the brain. Merck "should" be VERY concerned that their
"lucrative lung cancer space" is FAR from being THE answer!!!! Surely they NEED to add a conjunctive antibody to claim having a much more effective treatment and even more dominance of that space??
Ann: Updated investor presentation and attendance at Bioshares, page-60
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $18.51M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 654316 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 1586680 | 3 |
View Market Depth
| Last trade - 10.06am 08/05/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable